Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Neil LernerChief Accounting Officer | Compass TherapeuticsCMPX | Open-market buy | 09/24 | 09/25 | 2,500 sh | $1.14 | $2,850 | +0.6% |
Neil LernerChief Accounting Officer | Compass TherapeuticsCMPX | Open-market buyAmendment | 04/29 | 04/30 | 15,000 sh | $1.89 | $28,350 | +3.9% |
Jonathan AndermanGeneral Counsel | Compass TherapeuticsCMPX | Open-market buyAmendment | 04/29 | 04/30 | 25,000 sh | $1.89 | $47,250 | +14.6% |
Compass TherapeuticsCMPX | Open-market buy | 25/05/27 | 25/05/27 | 10,000 sh | $2.11 | $21,100 | +0.2% | |
Orbimed AdvisorsDirector | Compass TherapeuticsCMPX | Open-market sale | 25/04/09 | 25/04/11 | 3,571,428 sh | $1.59 | $5,678,570.52 | −100.0% |
Carl L. GordonDirector | Compass TherapeuticsCMPX | Open-market sale | 25/04/09 | 25/04/11 | 3,571,428 sh | $1.59 | $5,678,570.52 | −100.0% |
Neil LernerChief Accounting Officer | Compass TherapeuticsCMPX | Open-market buy | 25/04/07 | 25/04/08 | 20,000 sh | $1.42 | $28,400 | +6.7% |
Jonathan AndermanGen Counsel & Corporate Sec | Compass TherapeuticsCMPX | Open-market buy | 25/04/07 | 25/04/08 | 20,000 sh | $1.54 | $30,800 | +2000.0% |
Compass TherapeuticsCMPX | Open-market buy | 23/03/10 | 23/03/10 | 10,000 sh | $3.37 | $33,700 | +0.2% | |
Compass TherapeuticsCMPX | Open-market buy | 23/02/27 | 23/02/27 | 20,000 sh | $3.98 | $79,600 | +0.3% | |
Compass TherapeuticsCMPX | Open-market buy | 23/02/15 | 23/02/15 | 20,000 sh | $3.86 | $77,200 | +0.3% | |
Compass TherapeuticsCMPX | Open-market buy | 23/01/31 | 23/01/31 | 20,000 sh | $4.05 | $81,000 | +0.4% | |
Compass TherapeuticsCMPX | Open-market buy | 23/01/24 | 23/01/24 | 20,000 sh | $4.19 | $83,800 | +0.4% |
